BLCO - Bausch + Lomb Corporation
After hours:
| Previous close | 18.51 |
| Open | 18.63 |
| Bid | 18.47 x 800 |
| Ask | 18.50 x 1200 |
| Day's range | 18.39 - 18.67 |
| 52-week range | 12.20 - 19.96 |
| Volume | |
| Avg. volume | 411,234 |
| Market cap | 6.476B |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.30 |
| Earnings date | 03 May 2023 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 28.38 |
Business WireBausch + Lomb Announces New Scientific Data and Analyses Featuring Consumer, Vision Care and Pharmaceutical Products Will Be Presented During American Optometric Association's Optometry's Meeting
VAUGHAN, Ontario, June 08, 2023--Bausch + Lomb Corporation (NYSE/TSX: BLCO) ("Bausch + Lomb"), a leading global eye health company dedicated to helping people see better to live better, today announced that researchers will present the results of 11 scientific poster presentations involving the company’s consumer, vision care and pharmaceutical products during the American Optometric Association (AOA) Optometry’s Meeting e-posters Virtual Event, which is taking place from June 13-14, 2023. In ad
Business WireBausch + Lomb Launches Biotrue® Hydration Boost Contact Lens Rehydrating Drops in the United States
VAUGHAN, Ontario, June 06, 2023--Bausch + Lomb Corporation (NYSE/TSX: BLCO) ("Bausch + Lomb"), a leading global eye health company dedicated to helping people see better to live better, today announced the U.S. launch of Biotrue® Hydration Boost Contact Lens Rehydrating drops, the first and only preservative-free rehydrating drop in a multi-dose bottle that is indicated to lubricate and rewet soft contact lenses, including daily disposables, and rigid gas permeables.
Business WireBausch + Lomb Launches Bausch + Lomb INFUSE® Multifocal Silicone Hydrogel Contact Lenses in the United States
VAUGHAN, Ontario, June 05, 2023--Bausch + Lomb Corporation (NYSE/TSX: BLCO) ("Bausch + Lomb"), a leading global eye health company dedicated to helping people see better to live better, today announced the U.S. launch of Bausch + Lomb INFUSE® Multifocal silicone hydrogel (SiHy) daily disposable contact lenses. Featuring a next-generation material infused with ProBalance Technology™ for all-day comfort and the company’s unique 3-Zone Progressive™ design, the new lens addresses the dynamic vision
Business WireBausch + Lomb Announces Key Leadership Changes
VAUGHAN, Ontario, June 01, 2023--Bausch + Lomb Corporation (NYSE/TSX: BLCO) ("Bausch + Lomb" or the "Company"), a leading global eye health company dedicated to helping people see better to live better, announced a reshaping of its executive leadership team, including the elevation of all business unit heads. Luc Bonnefoy, senior vice president (SVP), Surgical; John Ferris, SVP, Consumer; and Yang Yang, SVP, Vision Care; will join the executive management team of the Company reporting directly t
Business WireBausch + Lomb and Novaliq Announce FDA Approval of MIEBO™ (Perfluorohexyloctane Ophthalmic Solution) for the Treatment of the Signs and Symptoms of Dry Eye Disease
VAUGHAN, Ontario & HEIDELBERG, Germany, May 18, 2023--FDA approves MIEBO (Perfluorohexyloctane Ophthalmic Solution) for the Treatment of the Signs and Symptoms of Dry Eye Disease.
Simply Wall St.The 6.3% return this week takes Bausch + Lomb's (NYSE:BLCO) shareholders one-year gains to 18%
The simplest way to invest in stocks is to buy exchange traded funds. But you can significantly boost your returns by...
Business WireBausch + Lomb Announces First-Quarter 2023 Results and Provides 2023 Guidance
VAUGHAN, Ontario, May 03, 2023--Bausch + Lomb Corporation, (NYSE/TSX: BLCO) ("Bausch + Lomb" or the "Company", "we" or "our"), a leading global eye health company dedicated to helping people see better to live better, today announced its first-quarter 2023 financial results.
Business WireBausch + Lomb Releases Annual Environmental, Social and Governance Report
VAUGHAN, Ontario, May 01, 2023--Bausch + Lomb Corporation, (NYSE/TSX: BLCO) ("Bausch + Lomb" or the "Company", "we" or "our"), a leading global eye health company dedicated to helping people see better to live better, today released its annual Environmental, Social and Governance (ESG) Report, highlighting the Company’s ongoing commitment to implement sustainable business practices and initiatives that support its stakeholders’ well-being.
Business WireBausch + Lomb Announces the Presentation of New Scientific Data on Products and Pipeline Programs at the American Society of Cataract and Refractive Surgery Annual Meeting
VAUGHAN, Ontario, April 26, 2023--Bausch + Lomb Corporation (NYSE/TSX: BLCO) ("Bausch + Lomb"), a leading global eye health company dedicated to helping people see better to live better, today announced the presentation of 21 podium presentations and four poster presentations related to the company’s products and pipeline programs during the American Society of Cataract and Refractive Surgery (ASCRS) annual meeting, which will take place in San Diego from May 5-8, 2023.
Business WireBausch + Lomb Announces 2023 Annual Meeting of Shareholder Results
VAUGHAN, Ontario, April 25, 2023--Bausch + Lomb Corporation (NYSE/TSX: BLCO) ("Bausch + Lomb" or the "Company"), a leading global eye health company dedicated to helping people see better to live better, today announced the election of the 10 directors nominated at its 2023 annual meeting of shareholders (the "Annual Meeting") held on April 24, 2023. The detailed results of the vote for the election of directors are set out below:
Business WireBausch + Lomb Announces U.S. Launch of StableVisc™ Cohesive Ophthalmic Viscosurgical Device and TotalVisc™ Viscoelastic System
VAUGHAN, Ontario, April 24, 2023--Bausch + Lomb Corporation (NYSE/TSX: BLCO) ("Bausch + Lomb"), a leading global eye health company dedicated to helping people see better to live better, today announced the U.S. launch of StableVisc™ cohesive ophthalmic viscosurgical device (OVD) as well as TotalVisc™ Viscoelastic System. StableVisc and TotalVisc provide eye surgeons with new options for dual-action protection during cataract surgery.
Business WireBausch + Lomb Announces the Presentation of New Data on Products and Pipeline Programs at the Association for Research in Vision and Ophthalmology Meeting
VAUGHAN, Ontario, April 20, 2023--Bausch + Lomb Corporation (NYSE/TSX: BLCO) ("Bausch + Lomb"), a leading global eye health company dedicated to helping people see better to live better, today announced the presentation of eight scientific poster presentations during the Association for Research in Vision and Ophthalmology (ARVO) annual meeting, which will take place in New Orleans from April 23-27, 2023.
- Simply Wall St.
Lacklustre Performance Is Driving Bausch + Lomb Corporation's (NYSE:BLCO) Low P/S
With a price-to-sales (or "P/S") ratio of 1.5x Bausch + Lomb Corporation ( NYSE:BLCO ) may be sending very bullish...
Business WireBausch + Lomb Reports More Than 65 Million Units of Contact Lens, Eye Care and Lens Care Materials Recycled Through ONE by ONE and Biotrue® Eye Care Recycling Programs
VAUGHAN, Ontario, April 18, 2023--Bausch + Lomb Corporation (NYSE/TSX: BLCO) ("Bausch + Lomb"), a leading global eye health company dedicated to helping people see better to live better, today announced its exclusive ONE by ONE and Biotrue® Eye Care Recycling programs have recycled a total of 65.8 million units, or 397,194 pounds, of used contact lenses, eye care and lens care materials, which is equivalent to the weight of three commercial-sized airplanes.
Business WireBausch + Lomb Will Release First-Quarter 2023 Financial Results on May 3
VAUGHAN, Ontario, April 17, 2023--Bausch + Lomb Corporation (NYSE/TSX: BLCO) ("Bausch + Lomb"), a leading global eye health company dedicated to helping people see better to live better, will release its first-quarter 2023 financial results on Wednesday, May 3, 2023. Bausch + Lomb will host a conference call and live web cast at 8:00 a.m. ET to discuss the results and provide a business update. All materials will be made available on the Investor Relations section of the Bausch + Lomb website pr
Business WireBausch + Lomb and Heidelberg Engineering Announce the Introduction of SeeLuma™ Fully Digital Surgical Visualization Platform
VAUGHAN, Ontario & HEIDELBERG, Germany, April 13, 2023--Bausch + Lomb, a leading global eye health company dedicated to helping people see better to live better, and Heidelberg Engineering, today announced the introduction of the SeeLuma™ Fully Digital Surgical Visualization Platform, which provides ophthalmic surgeons with a new level of visualization compared to optical, hybrid and retrofitted microscopes. Developed to facilitate even the most complex surgical procedures, SeeLuma will be intro
Business WireBausch + Lomb Appoints Bob Bailey as Executive Vice President and Chief Legal Officer and Andrew Stewart as President, Ophthalmic Pharmaceuticals
VAUGHAN, Ontario, April 12, 2023--Bausch + Lomb Corporation (NYSE/TSX: BLCO) ("Bausch + Lomb" or the "Company"), a leading global eye health company dedicated to helping people see better to live better, announced the appointments of Bob Bailey as executive vice president (EVP) and Chief Legal Officer and Andrew Stewart as president, Ophthalmic Pharmaceuticals, effective April 24, 2023. Both Mr. Bailey and Mr. Stewart will join the executive management team of the Company. Concurrent with these
Business WireBausch + Lomb and Novaliq Announce Publication of Second Pivotal Phase 3 Data on NOV03 (Perfluorohexyloctane) in American Journal of Ophthalmology
VAUGHAN, Ontario & HEIDELBERG, Germany, March 22, 2023--Bausch + Lomb Corporation (NYSE/TSX: BLCO) ("Bausch + Lomb"), a leading global eye health company dedicated to helping people see better to live better, and Novaliq GmbH, a biopharmaceutical company focusing on first- and best-in class ocular therapeutics, today announced that American Journal of Ophthalmology has published results from MOJAVE, the second pivotal Phase 3 trial for NOV03 (perfluorohexyloctane). NOV03 is being investigated to
- Simply Wall St.
Bausch + Lomb Full Year 2022 Earnings: EPS Misses Expectations
Bausch + Lomb ( NYSE:BLCO ) Full Year 2022 Results Key Financial Results Revenue: US$3.77b (flat on FY 2021). Net...
Business WireBausch + Lomb Announces Fourth-Quarter and Full-Year 2022 Results
VAUGHAN, Ontario, February 22, 2023--Bausch + Lomb Corporation, (NYSE/TSX: BLCO) ("Bausch + Lomb" or the "Company", "we" or "our"), a leading global eye health company dedicated to helping people see better to live better, today announced its fourth-quarter and full-year 2022 financial results.
Business WireBausch + Lomb Appoints Brent Saunders as Chief Executive Officer and Chair of the Board of Directors, Effective March 6, 2023
VAUGHAN, Ontario, February 15, 2023--Bausch + Lomb Corporation (NYSE/TSX: BLCO) ("Bausch + Lomb" or the "Company"), a leading global eye health company dedicated to helping people see better to live better, announced the appointment of Brent Saunders as chief executive officer ("CEO") and chair of the Board of Directors ("Board") of the Company, effective March 6, 2023. Concurrent with this appointment, and as previously announced, Joseph C. Papa will step down from his roles as CEO and director
- Business Wire
New Bausch + Lomb Social Media Campaign Highlights What ‘Sights’ Inspire AMD Patients
VAUGHAN, Ontario, February 07, 2023--Bausch + Lomb Corporation (NYSE/TSX: BLCO) ("Bausch + Lomb"), a leading global eye health company dedicated to helping people see better to live better, today announced a new social media campaign designed to raise awareness of Age-related Macular Degeneration (AMD), a leading cause of vision loss for those over age 501 and the leading cause of blindness for the 65+ population2. The campaign, ‘What Sight Inspires You’, will feature personal stories and sights
Business WireBausch + Lomb and Modulight Announce FDA Approval of ML6710i Photodynamic Laser for Use with Bausch + Lomb’s VISUDYNE® (Verteporfin for Injection)
VAUGHAN, Ontario & TAMPERE, Finland, February 01, 2023--Bausch + Lomb Corporation (NYSE/TSX: BLCO) ("Bausch + Lomb"), a leading global eye health company dedicated to helping people see better to live better, and Modulight Corporation ("Modulight"), a biomedical laser company, today announced that the U.S. Food and Drug Administration (FDA) has approved the ML6710i photodynamic laser for equivalent use with Bausch + Lomb’s VISUDYNE® (verteporfin for injection) photodynamic therapy (PDT) for the
Business WireBausch + Lomb Will Release Fourth-Quarter and Full-Year 2022 Financial Results on February 22
VAUGHAN, Ontario, January 23, 2023--Bausch + Lomb Corporation (NYSE/TSX: BLCO) ("Bausch + Lomb"), a leading global eye health company dedicated to helping people see better to live better, will release its fourth-quarter and full-year 2022 financial results on Wednesday, Feb. 22, 2023. Bausch + Lomb will host a conference call and live web cast at 8:00 a.m. ET to discuss the results and provide a business update. All materials will be made available on the Investor Relations section of the Bausc
Business WireBausch + Lomb Acquires AcuFocus, Inc.
VAUGHAN, Ontario & IRVINE, Calif., January 17, 2023--Bausch + Lomb Corporation (NYSE/TSX: BLCO) ("Bausch + Lomb"), a leading global eye health company dedicated to helping people see better to live better, and AcuFocus, Inc. ("AcuFocus"), a privately held ophthalmic medical device company, today announced that an affiliate of Bausch + Lomb has acquired AcuFocus, pursuant to a merger transaction with the parent company of AcuFocus.